TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Parietex TM Parastomal No Hole Mesh for Repair of Parastomal Hernias in End-colostomies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- adult patients, planned for primary elective laparoscopic hernia repair of an end-colostomy.~Exclusion Criteria:~* previous repair of a parastomal hernia at the same site~* emergency operations~* open parastomal hernia repair~* parastomal hernias at an ileostomy or an ileal conduit stoma~* loop colostomies~* patients under the age of 18 years~* pregnant women~* ASA score 4 or more~* no informed consent of the patient~* patients unable to complete the stoma Quality of Life assessment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Surgical Conditions During Vocal Cord Surgery Requiring Jet Ventilation With Moderate vs. Deep Neuromuscular Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective vocal cord resection with an expected length of the procedure longer than 20 minutes and requiring jet ventilation~Exclusion Criteria:~* Patients younger than 18 years old~* Patients unable to give written informed consent~* Patients with known or suspected neuromuscular disease~* Patients with allergies to medications to be used during anesthesia~* Patients with a (family) history of malignant hyperthermia~* Patients with renal insufficiency (serum creatinine \>2 times normal or a glomerular filtration rate \<60 ml/h)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Moderate neuromuscular blockade (MNB) (Type: ACTIVE_COMPARATOR): The goal is to realize a moderate NMB (TOF 1-2 twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.~This represents the standard care in our institution for this type of surgery. At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the moderate neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent).
- Deep neuromuscular blockade (MNB) (Type: ACTIVE_COMPARATOR): The goal is to realize a deep MNB (TOF zero twitches). NMB will be induced with a bolus dose of rocuronium (Non-depolarizing Skeletal Neuromuscular Blocking Agent). If the target TOF values was not reached bolus doses of rocuronium (5 mg) will be given to achieve the target.~At the end of surgery, neuromuscular blockade in all patients will be reversed by sugammadex: patients in the deep neuromuscular blockade group will receive sugammadex (Selective Relaxant Binding Agent).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Renal Denervation Hypertension After Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 18+ years old~* Clinical verified stroke within the last year~* Treatment resistant hypertension at 150 mm Hg or higher systolic at consultation~* Modified Ranking between 0-2~Exclusion Criteria:~* Lack of informed consent~* Renal artery anatomy, which prevents the procedure~* Reno vascular disease~* Pacemaker~* Haemodynamic vascular occlusion or valve disease~* Pregnancy or women in the childbearing age~* Secondary hypertension~* Mean systolic blood pressure over 180 mm Hg

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Combined LDR Boost and HDR Whole Gland

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed Adenocarcinoma of the prostate~* Single PIRADS 4 or 5 lesion on multiparametric MRI~* T1c-T2b on rectal exam~* Gleason 3+3 and PSA \< 20ng/mL~* Gleason 3+4 and PSA \<10ng/mL~* Less than 50% of the cores positive in an untargeted prostate biopsy.~* Prostate volume \< 60 cc~Exclusion Criteria:~* Incapable or ineligible for MRI imaging~* Previous trans-urethral resection of prostate (TURP)~* Previous or current use of androgen deprivation~* Baseline International Prostate Symptom Score (IPSS) \> 15~* Evidence of distant or nodal metastasis~* Disease that contraindicates treatment with radiation (e.g connective tissue disease)~* Unsuitable for anesthesia due to comorbidity

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDR/HDR (Type: EXPERIMENTAL): MRI planned LDR boost to DIL with concurrent whole gland 19 Gy HDR. LDR dose will be sequentially escalated from 50 Gy to 80 Gy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of the Tecaretherapy in Patients With Lateral Elbow Tendinopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient suffering from a chronic lateral elbow tendinopathy confirmed by echography~Exclusion Criteria:~Patients:~* with contra-indications for a Tecaretherapy (Pace maker, insuline pump, pregnancy, infection, fever, cancer, thrombophlebitis)~* reporting injections and/or shockwaves in the past (for the tendinopathy)~* with an associated neurogenic dysfunction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Conventional PT treatment (CPT) (Type: OTHER): All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching;
- CPT + Tecare (Type: EXPERIMENTAL): All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching (idem CPT group). However, an active Tecaretherapy is also provided during the sessions
- CPT + Placebo Tecare (Type: SHAM_COMPARATOR): All treatment sessions include massage, eccentric exercises by means of an isokinetic dynamometer and stretching (idem CPT group). However, an inactive Tecaretherapy is also provided during the sessions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Plaque Stabilization and Restoration by Bioresorbable Vascular Scaffold

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Symptomatic patients between the age of 18 and 80 years~* Morise Risk score of ≥9 (intermediate or high risk) but no proven ischemia (no positive troponin or ST-elevation)~* Intermediate coronary lesion on CT scan (50-70% based on CT estimate) and a plaque with at least two of the following vulnerability criteria: Napkin ring sign, positive remodeling, low attenuation and spotty calcification~* FFR negative lesion at coronary angiogram~* Vessel diameter ≥2.5 mm on visual estimate~* GFR ≥ 45mL/min/1.73m².~Exclusion Criteria:~* High calcium score on CT scan preventing adequate evaluation of the coronary lesion.~* Lesions located in a coronary vessels previously stented.~* Lesions located at a bifurcation~* lesions involving an epicardial side branch ≥2 mm in diameter by visual assessment~* the presence of thrombus or another clinically significant stenosis in the target vessel.~* Left main (\>50%) or known three vessel disease.~* Patients presenting with acute myocardial infarction, unstable arrhythmias, or patients who have a left ventricular ejection fraction \<30%~* Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparine or Everolimus and known true anaphylaxis to prior contrast media or known bleeding diathesis or known coagulopathy.~* Planned elective surgical procedure necessitating interruption of dual antiplatelet therapy during the first 6 months after inclusion.~* History of stent thrombosis~* Malignancies or other comorbidity with a life expectancy of less than one year or that may result in protocol noncompliance~* Pregnancy (present, suspected or planned) or positive pregnancy test (in women with childbearing potential a negative pregnancy test is mandatory)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Bioresorbable vascular scaffold (Type: EXPERIMENTAL): Implantation of Bioresorbable vascular scaffold in vulnerable plaques

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Two Oral Appliances in the Treatment of Sleep Apnea Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sufficient teeth to allow wearing of the device~* Mild to severe OSAS~* Ability to answer the questionnaires~* No concomitant CPAP treatment~* BMI inferior to 32 kg/m2~Exclusion Criteria:~* Important dental or parodontal disease~* Central sleep apnea~* Jaw opening limitations~* Temporo-mandibular joint dysfunction~* Major gag reflex precluding the long-term use of the device~* Major or unstable cardiovascular or pulmonary disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Propulsion type appliance (Herbst) (Type: EXPERIMENTAL): None
- Retention type appliance (ORM) (Type: ACTIVE_COMPARATOR): Retention type appliance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Tuberculosis in Prisons

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Age above 18 and under 45 at the time of inclusion;~* Sign the informed consent form.~Exclusion criteria:~* Be indigenous;~* Active TB or previous use of isoniazid;~* Score Alcohol Use Disorders Identification Test ≥15.~* Reactive serology for HIV, hepatitis B and C;~* Reactive result for quantiferon, considering as positive the result of Tube 1 and / or Tube22 above 0.2 IU / mL;~* Liver enzymes (Aspartate aminotransferase and Alanate aminotransferase) three times the upper limit;~* History or treatment for epilepsy;

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Treatment (Type: EXPERIMENTAL): Each subject received two oral supervised weekly doses of isoniazid 900 milligrams.
- Control (Type: PLACEBO_COMPARATOR): Each subject received two oral supervised weekly doses of placebo (oral tablet, without the active ingredient, similar in size, weight, color, taste and odor).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Symptomatic Therapy of Uncomplicated Lower Urinary Tract Infections in the Ambulatory Setting.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Age between 18 and 70 years~* Written informed consent~* At least one typical symptom of acute, lower urinary tract infection out of dysuria, frequency, macrohaematuria, cloudy or smelly urine or self-diagnosed cystitis~* A urine dipstick test should be indicative of UTI by positive nitrite or leucocyturia~Exclusion Criteria~* Duration of UTI symptoms for more than 7 days before physician's visit~* Clinical signs of invasiveness such as fever (axillary body temperature \>38 degrees Celsius), costovertebral pain or tenderness, rigors, nausea or vomiting~* Known or suspicion of anatomical or functional abnormality of the urinary tract~* Vaginal symptoms: discharge, irritation~* Diabetes mellitus~* Immunosuppression (e.g. prednisone equivalent \>10mg per day for \>14 days, chemotherapy, radiotherapy, immunomodulators, HIV infection, neutropenia)~* Any other serious comorbidity as judged by the treating physician~* Bladder catheter in situ or during the past 30 days~* Pregnancy~* Recurrent urinary tract infection (more than 3 infections during the last 12 months)~* Antibiotic treatment during the last 4 weeks~* Hypersensitivity to one of the study medications~* Psychiatric illness or dementia~* Unable to communicate in German or French language~* Documented coagulopathy (including therapy with coumarine derivatives) or documented history of gastric or duodenal ulcer disease~* Documented renal insufficiency grade III or higher (calculated GFR \<60) or known congestive heart failure (NYHA III or higher)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- antibiotic (Type: ACTIVE_COMPARATOR): Norfloxacin for three days, followed by fosfomycin on day 4 if deemed necessary
- symptomatic (Type: EXPERIMENTAL): Diclofenac retard for three days, followed by fosfomycin on day 4 if deemed necessary

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Outcomes of the Freedom Spinal Cord Stimulation (SCS) System for the Management of Chronic Back and Leg Pain

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Appropriate Freedom SCS candidate as affirmed by study investigator~* Candidate has a stable spine not suitable for further surgery as confirmed by physician~* 18 years of age or older (no upper age limit)~* Diagnosis of failed back surgery syndrome (FBSS) characterized by chronic, intractable pain of the legs, back, or both legs and back~* At least 6 months since last surgical procedure on the spine~* Average score of 60mm or greater on a VAS scale (Scale of 0 to 100, where 0 equals no pain and 100 equals worst possible pain)~* Pain duration of at least 6 months~* Expected lifespan of at least two years~* Able to comply with study requirements~* Gives informed consent for study participation~Exclusion Criteria:~* A consistent VAS score of 100 over the past 24 hours as established at Visit 1~* A co-existing condition that could increase the risk of SCS implantation (e.g., severe cardiac or respiratory disorders, coagulation disorder) or planned surgery within the study duration that could be compromised by SCS (e.g., diathermy)~* Pregnant or planning to become pregnant~* Known or suspected substance abuse within the last 2 years~* Major psychiatric disorder (untreated or refractory to treatment) in the investigators opinion~* Cognitive and/or behavioral issues that could impair study participation, (e.g., unreliability; defective memory; noncompliance in taking medications or keeping appointments; or impaired orientation to time, place, and events)~* Documented allergy to Freedom SCS material components~* Co-existing pain condition or participation in another clinical study that could confound the results of this study~* History of another implanted medical device (e.g., explanted spinal cord stimulator, peripheral nerve stimulation, sacral nerve stimulator, pacemaker, or intrathecal drug delivery)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Back Pain Only (Type: ACTIVE_COMPARATOR): Pain localized to the low back or buttocks.
- Leg Pain Only (Type: ACTIVE_COMPARATOR): Pain localized to unilateral pain of the leg (thigh, knee, calf, or foot).
- Back and Leg Pain (Type: ACTIVE_COMPARATOR): Pain localized to both the low back and legs (back, buttocks, thigh, knee, calf, or foot).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin-A as a Treatment for Chronic Muscle-Related Pain in Adults With Spastic Cerebral Palsy: a Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years.~* Spastic Cerebral Palsy.~* Chronic pain, related to spastic muscle. Chronic pain defined as: 1)Recurring regional pain for at least three months AND 2)Pain intensity on average for the last 24 hours ≥3 on Numerical Rating Scale.~* Signed Informed consent.~Exclusion Criteria:~* Allergy/hypersensitivity to Dysport® or any of its components.~* Pregnancy.~* Women who breastfeed their children.~* Treatment with Botulinum toxin-A within the last five months.~* If there has been dose changes in any muscle-tone altering medication within two weeks of Visit 1.~* A clear degenerative cause behind the pain as elucidated by the clinical examination (e.g. history of osteoarthritis).~* Intellectual disability and/or communication impairment that disable the individual from answering the questionnaires and giving informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Botulinum toxin-A (Dysport®) (Type: ACTIVE_COMPARATOR): Intramuscular injections of Botulinum toxin-A in spastic muscles with regional muscle-related pain
- Normal saline (Type: PLACEBO_COMPARATOR): Intramuscular injections of normal saline solution in spastic muscles with regional muscle-related pain

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Defining the Role of Insulin Resistance in 'Idiopathic' Dilated Cardiomyopathy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of nonischemic dilated cardiomyopathy, current NYHA class I-II congestive heart failure~* History of Stage C-D heart failure with EF ≤ 40% during the course of the disease~* Treatment with a stable comprehensive heart failure regimen for at least 3 months (including beta-blockers and ACE-inhibitors or angiotensin receptor blockers unless intolerant)~* Age \> 18 yrs~Exclusion Criteria:~* Cardiomyopathy due to one of the following:~  * Ischemic heart disease~ * Primary valvular lesion~ * Hypertrophic cardiomyopathy~* Cardiac resynchronization within the last 3 months~* Transaminase values \> 2.5 x upper limit of normal or history of liver disease~* Diagnosis of diabetes mellitus by:~  * Diabetes previously diagnosed per patient history~ * 2 or more fasting glucose values \> 125 mg/dl~* Current NYHA class III or IV heart failure~* Serum creatinine \> 1.6 mg/dl~* History of heart transplantation~* Pregnancy or active breast feeding~* Hospitalization for decompensated heart failure within 30 days prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues